Bhishamjit S Chera1,2, Robert J Amdur3,4, Joel E Tepper1,2, Xianming Tan2, Jared Weiss2,5, Juneko E Grilley-Olson2,5, D Neil Hayes6, Adam Zanation7, Trevor G Hackman7, Samip Patel7, Nathan Sheets8, Mark C Weissler7, William M Mendenhall3,4. 1. Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina. 2. UNC Lineberger Comprehensive Cancer Center, University of North Carolina Hospitals, Chapel Hill, North Carolina. 3. Department of Radiation Oncology, University of Florida Hospitals, Gainesville, Florida. 4. UF Health Shands Cancer Center, University of Florida Hospitals, Gainesville, Florida. 5. Division of Hematology Oncology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina. 6. Division of Hematology Oncology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. 7. Department of Otolaryngology/Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina. 8. Rex UNC Healthcare, Raleigh, North Carolina.
Abstract
BACKGROUND: The purpose of the current study was to determine quality of life and tumor control from a prospective phase 2 clinical trial evaluating deintensified chemoradiotherapy for favorable risk, human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. METHODS: Patients with T0-T3, N0-N2c, M0, p16-positive disease and a minimal smoking history were treated with 60 grays of intensity-modulated radiotherapy with concurrent weekly intravenous cisplatin (30 mg/m2 ). The primary study endpoint was the pathologic complete response rate based on biopsy of the primary site and dissection of pretreatment positive lymph node regions. The pathologic complete response rate as previously reported was 86%. Herein, the authors report secondary endpoint measures of local control, regional control, cause-specific survival, distant metastasis-free survival, and overall survival, and patient-reported outcomes (European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire [EORTC QLQ-C30] and the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events [PRO-CTCAE]). RESULTS: A total of 44 patients enrolled with a median follow-up of 36 months (88% with ≥2 years). The 3-year local control, regional control, cause-specific survival, distant metastasis-free survival, and overall survival rates were 100%, 100%, 100%, 100%, and 95%, respectively. The mean before and 3-year after EORTC QOL scores were: global: 80 of 78; swallowing: 11 of 11; dry mouth: 16 of 41; and sticky saliva: 6 of 29. The mean before and 3-year after PRO-CTCAE scores were: swallowing: 0.4 of 0.7; and dry mouth: 0.4 of 1.4. Approximately 39% of patients required a feeding tube (median duration, 15 weeks; none were permanent). There were no ≥grade 3 late adverse events reported. CONCLUSIONS: For patients with favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma, a substantially decreased intensity of therapy with 60 grays of intensity-modulated radiotherapy and weekly low-dose cisplatin produced better preservation of quality of life compared with standard therapies while maintaining excellent 3-year tumor control and survival. Cancer 2018;124:2347-54.
BACKGROUND: The purpose of the current study was to determine quality of life and tumor control from a prospective phase 2 clinical trial evaluating deintensified chemoradiotherapy for favorable risk, human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. METHODS:Patients with T0-T3, N0-N2c, M0, p16-positive disease and a minimal smoking history were treated with 60 grays of intensity-modulated radiotherapy with concurrent weekly intravenous cisplatin (30 mg/m2 ). The primary study endpoint was the pathologic complete response rate based on biopsy of the primary site and dissection of pretreatment positive lymph node regions. The pathologic complete response rate as previously reported was 86%. Herein, the authors report secondary endpoint measures of local control, regional control, cause-specific survival, distant metastasis-free survival, and overall survival, and patient-reported outcomes (European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire [EORTC QLQ-C30] and the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events [PRO-CTCAE]). RESULTS: A total of 44 patients enrolled with a median follow-up of 36 months (88% with ≥2 years). The 3-year local control, regional control, cause-specific survival, distant metastasis-free survival, and overall survival rates were 100%, 100%, 100%, 100%, and 95%, respectively. The mean before and 3-year after EORTC QOL scores were: global: 80 of 78; swallowing: 11 of 11; dry mouth: 16 of 41; and sticky saliva: 6 of 29. The mean before and 3-year after PRO-CTCAE scores were: swallowing: 0.4 of 0.7; and dry mouth: 0.4 of 1.4. Approximately 39% of patients required a feeding tube (median duration, 15 weeks; none were permanent). There were no ≥grade 3 late adverse events reported. CONCLUSIONS: For patients with favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma, a substantially decreased intensity of therapy with 60 grays of intensity-modulated radiotherapy and weekly low-dose cisplatin produced better preservation of quality of life compared with standard therapies while maintaining excellent 3-year tumor control and survival. Cancer 2018;124:2347-54.
Authors: Carryn M Anderson; Randall J Kimple; Alexander Lin; Sana D Karam; Danielle N Margalit; Melvin L K Chua Journal: Int J Radiat Oncol Biol Phys Date: 2019-07-15 Impact factor: 7.038
Authors: Maura L Gillison; Andy M Trotti; Jonathan Harris; Avraham Eisbruch; Paul M Harari; David J Adelstein; Richard C K Jordan; Weiqiang Zhao; Erich M Sturgis; Barbara Burtness; John A Ridge; Jolie Ringash; James Galvin; Min Yao; Shlomo A Koyfman; Dukagjin M Blakaj; Mohammed A Razaq; A Dimitrios Colevas; Jonathan J Beitler; Christopher U Jones; Neal E Dunlap; Samantha A Seaward; Sharon Spencer; Thomas J Galloway; Jack Phan; James J Dignam; Quynh Thu Le Journal: Lancet Date: 2018-11-15 Impact factor: 79.321
Authors: Adam R Burr; Paul M Harari; Alyx M Haasl; Aaron M Wieland; Justine Y Bruce; Randall J Kimple; Gregory K Hartig; Timothy M McCulloch; Matthew E Witek Journal: Head Neck Date: 2020-02-14 Impact factor: 3.147
Authors: Bhishamjit S Chera; Sunil Kumar; Brian T Beaty; David Marron; Stuart Jefferys; Rebecca Green; Emily C Goldman; Robert Amdur; Nathan Sheets; Roi Dagan; D Neil Hayes; Jared Weiss; Juneko E Grilley-Olson; Adam Zanation; Trevor Hackman; Jeffrey M Blumberg; Samip Patel; Mark Weissler; Xianming M Tan; Joel S Parker; William Mendenhall; Gaorav P Gupta Journal: Clin Cancer Res Date: 2019-05-14 Impact factor: 12.531
Authors: Thong Chotchutipan; Benjamin S Rosen; Peter G Hawkins; Jae Y Lee; Anjali L Saripalli; Dharmesh Thakkar; Avraham Eisbruch; Issam El Naqa; Michelle L Mierzwa Journal: Head Neck Date: 2018-12-12 Impact factor: 3.147
Authors: Lauren J Beesley; Peter G Hawkins; Lahin M Amlani; Emily L Bellile; Keith A Casper; Steven B Chinn; Avraham Eisbruch; Michelle L Mierzwa; Matthew E Spector; Gregory T Wolf; Andrew G Shuman; Jeremy M G Taylor Journal: Cancer Date: 2018-10-06 Impact factor: 6.860